Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering

JAMA. 2016 Nov 15;316(19):1967-1968. doi: 10.1001/jama.2016.16575.

Authors

Fatima Rodriguez¹, Robert A Harrington²

Affiliations

¹ Division of Cardiovascular Medicine, Stanford University, Stanford, California.
² Division of Cardiovascular Medicine, Stanford University, Stanford, California2Department of Medicine, Stanford University, Stanford, California.

PMID: 27838727
DOI: 10.1001/jama.2016.16575

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cardiovascular Diseases / epidemiology
Cardiovascular Diseases / prevention & control*
Cholesterol, LDL / drug effects*
Clinical Trials as Topic
Enzyme Inhibitors / therapeutic use*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Medication Adherence
PCSK9 Inhibitors*
Risk Assessment
Risk Reduction Behavior

Substances

Cholesterol, LDL
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
PCSK9 Inhibitors
PCSK9 protein, human